Opening book details…
Can I read Resistance to Targeted Therapies in Breast Cancer (Resistance to Targeted Anti-Cancer Therapeutics, 16) on EtoBox?
Resistance to Targeted Therapies in Breast Cancer (Resistance to Targeted Anti-Cancer Therapeutics, 16) by Jenifer R. Prosperi (eds.) is a nonfiction available to read on EtoBox.
What is Resistance to Targeted Therapies in Breast Cancer (Resistance to Targeted Anti-Cancer Therapeutics, 16) about?
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. #xE000
Who reads Resistance to Targeted Therapies in Breast Cancer (Resistance to Targeted Anti-Cancer Therapeutics, 16)?
It is typically read by self-directed learners exploring a subject in depth.
Common subject areas: history, science, philosophy, social sciences.
- Author
- Jenifer R. Prosperi (eds.)
- Publisher
- Springer International Publishing : Imprint : Springer
- Published
- 2017
- Language
- EN
- ISBN
- 9783319701417
- Category
- nonfiction
- Subjects
- Medical, Medicine
More by Jenifer R. Prosperi (eds.)
Browse all works by Jenifer R. Prosperi (eds.)
Similar books
- Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance (Resistance to Targeted Anti-Cancer Therapeutics Book 1) — Khyati Kapoor, Hong May Sim (auth.), Benjamin Bonavida (2013)
- Targeted Therapies in Breast Cancer (Oxford American Pocket Notes) — Harold J. Burstein (2011)
- Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance (Resistance to Targeted Anti-Cancer Therapeutics) — Q. Ping Dou (2014)
- Resistance to Molecular Therapies for Hepatocellular Carcinoma (Resistance to Targeted Anti-Cancer Therapeutics (13)) — Augusto Villanueva (2017)
- Current Applications for Overcoming Resistance to Targeted Therapies — Myron R. Szewczuk, Bessi Qorri, Manpreet Sambi (2019)
- Resistance to Targeted Therapies Against Adult Brain Cancers — Amanda Tivnan (2016)